HIGHLIGHTS
- who: Consolato M. Sergi from the s Hospital of University of Hospital, Edmonton, AB T G , Canada have published the research: NLRP-3 Inflammasome: A Key Target, but Mostly Overlooked Following SARS-CoV-2 Infection, in the Journal: Vaccines 2022, 10, 1307. of /2022/
SUMMARY
Such a drug inhibits inflammatory cytokines such as IL-1, IL-6, and TNF-alpha, with favorable in_vitro studies and in_vivo studies showing clinical improvements and decreases in viral loads in COVID-19 patients. There is some growing evidence that targeting the NLRP3 (nucleotide-binding domain leucine-rich . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.